Skip to main content

Table 3 Average annual expenditure per patient

From: Impact of orphan drugs on Latvian budget

Trade Name Active Substance Average annual expenditure per patient (EUR)
Glivec Imatinib 30 420; 7 756a
Sprycel Dasatinib 49 530; 60 450a
Tasigna Nilotinib 47 409
Wilzin Zinc 1 534; 495a
Mozobil Plerixafor 12 796
Nplate Romiplostim 13 687
Elaprase Idursulfase 580 952
Myozyme Alglucosidase alfa 71 548
Increlex Mecasermin 40 233
Kuvan Sapropterin 43 121
Votubia Everolimus 34 802
Cystadane Betaine 6 315; 3 432a
Revatio Sildenafil 6 185
Volibris Ambrisentan 10 434
Tracleer Bosentan 12 697
Diacomit Stiripentol 7 295
Arzerra Ofatumumab 13 915
Atriance Nelarabine 12 386
Nexavar Sorafenib 10 535
Exjade Deferasirox 6 527
Revolade Eltrombopag 3 790
  1. aIndicates the individual reimbursement, if a drug was provided through multiple reimbursement mechanisms